CYTEIR THERAPEUTICS, INC.
128 Spring Street, Building A, Suite 510
Lexington, MA 02421
August 12, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
| Re: | Cyteir Therapeutics, Inc. |
Registration Statement on Form S-3 (File No. 333-266676)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Cyteir Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-266676) (the “Registration Statement”), so that it will be declared effective at 4:00 p.m. Eastern Time on August 16, 2022, or as soon as possible thereafter. The Company hereby authorizes Marc Rubenstein and Tara Fisher, counsel to the Company, to orally modify or withdraw this request for acceleration.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would inform Tara Fisher of Ropes & Gray LLP, counsel to the Company, at (617) 235-4824.
Very truly yours, | ||
CYTEIR THERAPEUTICS, INC. | ||
By: | /s/ Adam M. Veness Esq. | |
Adam M. Veness, Esq. | ||
General Counsel and Secretary | ||
